Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions reflect a balanced view, with some comments noting the promising two-year survival rates and tolerability, using phrases like 'potential breakthrough' or 'hopeful developments,' while others simply acknowledge the publication without deep elaboration. The tone varies from cautious optimism to mild interest, which aligns with the moderate scores assigned.
Most discussions recognize the promising response rates and manageable toxicity, indicating general agreement with the positive implications of the study.
Comments show a moderate level of curiosity, with some users highlighting the relevance of the treatment for rare cancers but not expressing deep passion.
Posts tend to briefly acknowledge the study's findings without detailed analysis, reflecting a neutral level of engagement.
Participants suggest the research could influence future treatment options, but the overall tone remains cautious, indicating perceived moderate impact.
Online now: PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers https://t.co/fwDCOcf5uS
Online now: PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers https://t.co/O5Tw51WVgz
A breakthrough in cancer treatment is here. Combining immunotherapy with chemotherapy researchers are making significant strides in treating aggressive small cell cancers in the bladder and prostate.
RT @CellRepMed: Online now: PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate…
Online now: PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers https://t.co/fwDCOcf5uS
Online now: PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers https://t.co/O5Tw51WVgz